TITLE

Clinical trial: active control vs placebo--What is ethical?

AUTHOR(S)
Splawinski, Jacek; Kuzniar, Jerzy
PUB. DATE
January 2004
SOURCE
Science & Engineering Ethics;Jan2004, Vol. 10 Issue 1, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The quest for effective medicines is very old. In modern times two important tools have been developed to evaluate efficacy of' drugs: superiority and non-inferiority types of clinical trials. The former tests the null hypothesis of μ (the difference between a tested drug and comparator) ≤ 0 against μ > 0; the latter tests the null hypothesis of μ ≤ - Δ against, μ > - Δ, where Δ is the clinical difference from the comparator. In a superiority trial, a new drug is tested against a placebo; in a non-inferiority trial, a new drug is tested against active treatment. In this paper, arguments are presented to show that a superiority trial against a placebo is scientifically sound but ethically unacceptable, whereas a non-inferiority trial against active treatment is ethically sound but scientifically not reliable. Switching from a superiority type of trial with placebo to a non-inferiority trial with an active-control - following the latest revision of Declaration of Helsinki - is in practice switching from the violation of the uncertainty principle to uncertainty of results. Given human and financial resources, it appears an academic question as to which is more unethical: to violate patients' rights or to produce results without scientific value. All presented considerations lead to the conclusion that the use of a superiority trial of design with an active control instead of placebo will satisfy scientific needs, expectation of patients, and the ancient quest for effective medicines. In the era of Good (Clinical, Laboratory, Manufacture) Practice, the attention of those performing clinical trials is focused on the procedure, not always on its essence. However even the excellent performance of a trial which is not worth doing is fruitless.
ACCESSION #
12724290

 

Related Articles

  • Applying Evidence to Support Ethical Decisions: Is the Placebo Really Powerless? Porzsolt, Franz; Schlotz-Gorton, Nicole; Biller-Andorno, Nikola; Thim, Anke; Meissner, Karin; Roeckl-Wiedmann, Irmgard; Herzberger, Barbara; Ziegler, Renatus; Gaus, Wilhelm; Pöppel, Ernst // Science & Engineering Ethics;Jan2004, Vol. 10 Issue 1, p119 

    Using placebos in day-to-day practice is an ethical problem. This paper summarises the available epidemiological evidence to support this difficult decision. Based on these data we propose to differentiate between placebo and "knowledge framing". While the use of placebo should be confined to...

  • The Ethics of Single Blind Trials. Heckerling, Paul S. // IRB: Ethics & Human Research;Jul/Aug2005, Vol. 27 Issue 4, p12 

    Presents an example of a single-blind trial similar to one encountered by our Institutional Review Board, to discuss some of the ethical issues that such a trial presents, and make recommendations for weighing the risks, benefits, and harms associated with single-blind trials. Definition of a...

  • Placebos and the UK Medical Research Council--and the consumer perspective. Box, Joan E. // Science & Engineering Ethics;Jan2004, Vol. 10 Issue 1, p95 

    The UK Medical Research Council, in order to further its mission of maintaining and improving human health, supports a substantial number of clinical trials on a wide variety of medical questions; some of these trials involve the use of placebos as controls or to maintain blinding. Before...

  • Use of placebo in clinical trials.  // WHO Drug Information;2001, Vol. 15 Issue 2, p70 

    Discusses the use of placebo in clinical trials, under the revised Declaration of Helsinki. Conditions that govern and restrict the use of placebo in order to avoid unethical use of placebo; Need to respect the patient's right to withdraw at any time, but still receive conventional treatment.

  • The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials -- A secondary analysis. Walach, Harald; Sadaghiani, Catarina; Dehm, Cornelia; Bierman, Dick // BMC Medical Research Methodology;2005, Vol. 5, p26 

    Background and purpose: Placebo response rates in clinical trials vary considerably and are observed frequently. For new drugs it can be difficult to prove effectiveness superior to placebo. It is unclear what contributes to improvement in the placebo groups. We wanted to clarify, what elements...

  • Baseline characteristics and patient reported outcome data of patients prescribed etanercept: web-based and telephone evaluation. Wade, Alan G.; Crawford, Gordon M.; Pumford, Neil; Koscielny, Volker; Maycock, Susan; McConnachie, Alex // BMC Medical Research Methodology;2011, Vol. 11 Issue 1, p91 

    Background: The anti-TNF inhibitor, etanercept is administered as a once or twice weekly subcutaneous injection for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis (JIA). Limited data from the patients' perspective...

  • QRXPHARMA BEGINS PHASE III CLINICAL TRIAL FOR PAIN THERAPY.  // Worldwide Biotech;Jan2008, Vol. 20 Issue 1, p1 

    The article reports on the Phase III clinical trial conducted by QRxPharma for its lead product candidate Q8003IR, an immediate release dual-opioid pain therapy. The trial involved a double-blind, placebo-controlled study that aims to compare the efficacy and safety of four different dosage...

  • A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial. Salvatorelli, Nicola; García-Larrosa, alejandro; allegrini, alessandro; Pavone, Daniele // Urologia Internationalis;Oct2016, Vol. 97 Issue 3, p347 

    Objective: To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a crosslinked protein) in the prevention of uncomplicated cystitis recurrences. Methods: Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture...

  • Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p67 

    The article reports on the results of the Toviaz, fesoterodine fumarate, Study A0221048 by Pfizer Inc. The study aims to determine the effectiveness and safety of a flexible dose regimen for patients with overactive bladder including nocturnal urinary urgency. It also reveals that treatment with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics